Skip to main content
OpenTrials
Completed

NCT Number: NCT02517307

Fatty Acid Oxidation Defects and Insulin Sensitivity

The purpose of this study is to learn more about what causes insulin resistance. It has been suggested that proper breakdown of fat into energy (oxidation) in the body is important to allow insulin to keep blood sugar in the normal range. The investigators want to know if having one of the fatty acid oxidation disorders could have an influence on insulin action. Fatty acid oxidation disorders are genetic disorders that inhibit one of the enzymes that converts fat into energy. The investigators will study both normal healthy people and people with a long-chain fatty acid oxidation disorder.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Very Long-chain Acyl-CoA Dehydrogenase Deficiency Carnitine Palmitoyltransferase II Deficiency, Late-Onset Carnitine Palmitoyltransferase II Deficiency, Myopathic Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency Medium chain acyl CoA dehydrogenase deficiency Medium-chain Acyl-CoA Dehydrogenase Deficiency Normal Volunteers Trifunctional Protein Deficiency Trifunctional Protein Deficiency With Myopathy And Neuropathy VLCAD deficiency

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Oregon Health & Science University

Portland, Oregon, 97239, United States

About this study

The overall goal of this proposal is to investigate the effects of disordered mitochondrial fatty acid oxidation on insulin resistance in humans. Mitochondrial dysfunction has been implicated in the development of insulin resistance and type 2 diabetes during excess dietary fat intake and from increased release of endogenous free fatty acids , such as occurs in obesity. Controversy exists, however, as to whether this insulin resistance results from intrinsic defects in mitochondrial energy utilization or from abnormalities resulting from excess free fatty acid flux, as well as the role that subsequent accumulation of cellular metabolic intermediates play in impaired insulin signaling.

To address these controversies, the investigators will study a unique population of patients with inherited defects in each of the three mitochondrial enzymes in the fatty acid oxidation pathway: 1) very long-chain acyl-CoA dehydrogenase (VLCAD); 2) trifunctional protein (TFP, which includes long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD)); and 3) medium-chain acyl-CoA dehydrogenase (MCAD). These proteins are required for the oxidation of sequentially shorter fatty acids . The investigators will test the hypothesis that intrinsic defects in mitochondrial function involving oxidation of long-chain, but not medium-chain, fatty acids are sufficient to prevent intralipid-induced insulin resistance.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • confirmed diagnosis of VLCAD, LCHAD, TFP or MCAD deficiency or same gender, age and BMI as a subject with a fatty acid oxidation disorder
  • ability to travel to Oregon Health & Science University, Portland, Oregon
  • ability and willingness to complete the protocol

Exclusion criteria

  • hemoglobin <10g/dl, international normalized ratio (INR) >1.2 Prothrombin time (PTT) >36 sec, Platelets <150K/mm3
  • pregnant or lactating females
  • endocrine disorder such as diabetes or untreated thyroid disease
  • cardiovascular disease or elevated plasma lipids
  • regularly taking meds that strongly affect bleeding, bruising or platelets

Treatment and study plan

Intralipid/Heparin

Drug

Co-infusion of intralipid and heparin solutions during a hyperinsulinemic euglycemic clamp

Glycerol/Saline

Drug

Co-infusion of a glycerol/saline solutions during a hyperinsulinemic euglycemic clamp

Hyperinsulinemic euglycemic clamp

Drug

Infusion of insulin at at 40 mU/m2/min for 5 hours. Blood glucose will be monitored every 5 min during the insulin infusion and euglycemia will be maintained throughout the clamp by infusing 20% dextrose at a variable rate.

Primary outcomes

  1. Glucose Disposal Rate (Rd)- the Rate of Glucose Infusion to Maintain Euglycemia During Steady State Insulin Infusion in mg/Min

    Time frame: Calculated during the last 30 minutes of a 300 minute clamp.

    Insulin infusion induces glucose disposal into muscle and adipose tissue in insulin sensitive participants. During the glycerol co-infusion, glucose disposal will be high. Intralipid co-infusion can induce a temporary insulin resistant state. During the intralipid co-infusion, glucose disposal will be decreased. We are comparing how intralipid dampens glucose disposal between participants with a FAOD and matched control participants. Glucose disposal is measured by measuring the ratio of deuterated glucose to unlabeled glucose at the beginning and end of the clamp. The calculated glucose disposal rate or RD is mg of glucose taken into muscle and adipose tissue per minute.

Secondary outcomes

  1. Endogenous Glucose Production (Ra) - Calculated by the Equations of Steele During Steady State in mg/Min

    Time frame: Calculated during the last 30 minutes of a 300 minute clamp.

    Infusion of insulin will suppress endogenous glucose production from the liver in insulin sensitive people. Insulin infusion with glycerol should suppress the endogenous glucose production in the liver but intralipid induces a temporary state of insulin resistance and the decrease in endogenous glucose production or Ra will be blunted with intralipid co-infusion. We are looking at the difference in Ra with intralipid between participants with a FAOD and matched control participants. Ra or endogenous glucose production during high insulin is measured in mg new glucose synthesized per minute.

Sponsors and collaborators

Lead sponsor

Oregon Health and Science University

Other

Registry information

Official study title

Role of Fatty Acid Oxidation Defects in Insulin Sensitivity

Important dates

Study start
2016
Primary completion
2021
Study completion
2021
First posted
Aug 7, 2015
Registry last updated
Jan 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.